Welcome to our dedicated page for Palvella Therapeutics news (Ticker: PVLA), a resource for investors and traders seeking the latest updates and insights on Palvella Therapeutics stock.
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing investigational topical therapies for serious, rare skin diseases and vascular malformations that currently have no FDA-approved treatments. News about Palvella often centers on progress across its QTORIN™ platform, including clinical trial milestones, regulatory designations, and pipeline expansion.
The company’s lead candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being studied in the Phase 3 SELVA trial for microcystic lymphatic malformations and in the Phase 2 TOIVA trial for cutaneous venous malformations, with additional development planned in clinically significant angiokeratomas. Updates on these programs include topline clinical results, details on trial design, and commentary from investigators and company leadership on efficacy and safety findings.
Palvella also reports news on its second product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis, including announcements of its selection as a new QTORIN-derived therapy and plans for Phase 2 clinical evaluation. Regulatory and grant-related news, such as FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations and Orphan Products Grant funding, provide additional context on how regulators view the unmet need in the company’s target indications.
Investors and observers following PVLA news can expect coverage of quarterly financial results, corporate updates, leadership appointments in areas like medical affairs and innovation, and participation in healthcare conferences. This news stream helps track how Palvella advances its investigational programs, manages its development priorities, and positions its QTORIN™ platform within the rare dermatologic disease landscape, while consistently noting that its product candidates remain investigational and unapproved.
Palvella Therapeutics (Nasdaq: PVLA) announced that Founder and CEO Wes Kaupinen will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET. A live webcast and 90-day replay will be accessible via the Events and Presentations section of Palvella's website.
Palvella Therapeutics (Nasdaq: PVLA) reported Q2 2026 results and a broad clinical and regulatory update. The company submitted the first module of its rolling NDA to the FDA for QTORIN™ rapamycin in microcystic lymphatic malformations, under Breakthrough Therapy and Fast Track designations, and remains on track to complete the NDA in the second half of 2026. Palvella is preparing for a planned standalone U.S. commercial launch in the first half of 2027, if approved. Additional milestones include planned Phase 3 initiation in cutaneous venous malformations in Q4 2026, ongoing Phase 2 LOTU trial in angiokeratomas, and a Phase 2 trial of QTORIN™ pitavastatin in DSAP expected to start in the second half of 2026. As of June 30, 2026, cash, cash equivalents and short-term investments totaled $250.6 million. Q2 2026 research and development expenses were $12.5 million and general and administrative expenses were $8.9 million, leading to a net loss of $21.9 million, or $1.52 per share.
Palvella Therapeutics (Nasdaq: PVLA) announced that its Chief Scientific Officer, Jeffrey Martini, Ph.D., has been selected to provide public comment at the FDA public workshop “Drug Repurposing: Considerations for Selection Criteria and Prioritization” on August 5, 2026, in Washington, D.C.
According to Palvella, Dr. Martini will address evidence frameworks and regulatory approaches for advancing repurposed therapies, particularly for serious, rare diseases with significant unmet medical needs. The hybrid meeting, convened by the Reagan-Udall Foundation in collaboration with FDA, will examine how to identify, prioritize, and efficiently advance repurposing candidates using existing safety profiles and real-world evidence.
Palvella Therapeutics (Nasdaq: PVLA) will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Management will host an investor conference call and webcast at 8:30 a.m. ET that day, with online and phone access plus a 90-day replay.
Palvella Therapeutics (Nasdaq: PVLA) appointed Matt Pauls, J.D., M.B.A., to its Board of Directors. Pauls brings over 25 years of biopharma experience advancing and commercializing therapies for serious and rare diseases.
His background includes CEO and Board roles at Savara, Strongbridge, Soleno, and senior commercial posts at Insmed, Shire, Bristol Myers Squibb, and Johnson & Johnson.
Palvella Therapeutics (Nasdaq: PVLA) submitted the first module of its rolling New Drug Application to the FDA for QTORIN™ 3.9% rapamycin gel to treat microcystic lymphatic malformations. Palvella targets completion of the NDA in 2H 2026 and a potential standalone US launch in 1H 2027, if approved.
QTORIN™ rapamycin is backed by a Phase 3 SELVA study with highly statistically significant results across all endpoints and favorable tolerability, and holds FDA Breakthrough Therapy, Orphan Drug, Fast Track designations plus an Orphan Products Development grant, addressing an estimated >30,000 US patients.
Palvella Therapeutics (Nasdaq: PVLA) announced that the FDA has granted rolling review for its planned NDA for QTORIN™ rapamycin to treat microcystic lymphatic malformations (microcystic LMs).
The company expects to complete the NDA submission in the second half of 2026; QTORIN has Breakthrough Therapy, Fast Track and Orphan Drug designations.
ResVita Bio appointed John D. Doux, M.D., M.B.A., to its Board of Directors as the company prepares to enter the clinic with RVB-003 for Netherton Syndrome. ResVita develops topical cell therapies using living, genetically engineered bacteria to deliver continuous protein therapeutics for chronic and rare skin diseases.
Dr. Doux is a board-certified dermatologist, healthcare investment analyst, and advocate for rare skin disease therapies, with extensive board and leadership experience across dermatology-focused organizations.
Palvella Therapeutics (Nasdaq: PVLA) completed its FDA pre-NDA meeting for QTORIN™ 3.9% rapamycin gel in microcystic lymphatic malformations and remains on track to submit an NDA in the second half of 2026.
The planned NDA will rely on Phase 3 SELVA data, supportive Phase 2 results, real-world evidence, and existing Breakthrough Therapy, Orphan Drug, Fast Track designations, with no additional efficacy study planned.
Palvella Therapeutics (Nasdaq: PVLA) announced that CEO and Founder Wes Kaupinen will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 9, 2026, at 8:40 a.m. ET.
A live and archived webcast will be available on Palvella's website.